Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy

被引:0
|
作者
De Lucia, Anna [1 ]
Mazzotti, Lucia [1 ,2 ]
Gaimari, Anna [1 ,2 ]
Zurlo, Matteo [1 ]
Maltoni, Roberta [3 ]
Cerchione, Claudio [4 ]
Bravaccini, Sara [5 ]
Delmonte, Angelo [6 ]
Crino, Lucio [6 ]
de Souza, Patricia Borges [1 ]
Pasini, Luigi [1 ,10 ]
Nicolini, Fabio [1 ]
Bianchi, Fabrizio [7 ]
Juan, Manel [8 ]
Calderon, Hugo [8 ]
Magnoni, Chiara [1 ,2 ]
Gazzola, Luca [1 ,2 ]
Ulivi, Paola [9 ]
Mazza, Massimiliano [1 ]
机构
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Adv Cellular Therapies & Rare Tumors Unit, Meldola, Italy
[2] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Healthcare Adm, Meldola, Italy
[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Hematol Unit, Meldola, Italy
[5] Kore Univ Enna, Dept Med & Surg, Enna, Italy
[6] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Med Oncol Dept, Meldola, Italy
[7] Fdn IRCCS Casa Sollievo Sofferenza, Unit Canc Biomarker, San Giovanni Rotondo, FG, Italy
[8] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Dept Immunol, Barcelona, Spain
[9] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Translat Oncol Unit, Meldola, Italy
[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Meldola, FC, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
non-small cell lung cancer (NSCLC); tumor microenvironment (TME); tyrosine kinase inhibitors (TKIs); immune checkpoint inhibitors (ICIs); chimeric antigen receptor (CAR) T cell therapy; CHIMERIC ANTIGEN RECEPTOR; CAR-T-CELLS; TERTIARY LYMPHOID STRUCTURES; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; EGFR-MUTATION; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; IMMUNE CELLS; SOLID TUMORS;
D O I
10.3389/fimmu.2025.1515748
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies for early detection and wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for NSCLC. Nowadays, targeted therapies remain the gold standard for many patients, but still they suffer from many adverse effects, including unexpected toxicity and intrinsic acquired resistance mutations, which lead to relapse. The adoption of immune checkpoint inhibitors (ICIs) in 2015, has offered exceptional survival benefits for patients without targetable alterations. Despite this notable progress, challenges remain, as not all patients respond favorably to ICIs, and resistance to therapy can develop over time. A crucial factor influencing clinical response to immunotherapy is the tumor microenvironment (TME). The TME is pivotal in orchestrating the interactions between neoplastic cells and the immune system, influencing tumor growth and treatment outcomes. In this review, we discuss how the understanding of this intricate relationship is crucial for the success of immunotherapy and survey the current state of immunotherapy intervention, with a focus on forthcoming and promising chimeric antigen receptor (CAR) T cell therapies in NSCLC. The TME sets major obstacles for CAR-T therapies, creating conditions that suppress the immune response, inducing T cell exhaustion. To enhance treatment efficacy, specific efforts associated with CAR-T cell therapy in NSCLC, should definitely focus TME-related immunosuppression and antigen escape mechanisms, by combining CAR-T cells with immune checkpoint blockades.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Moya-Horno, Irene
    Viteri, Santiago
    Karachaliou, Niki
    Rosell, Rafael
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [2] Targeted Therapies for Advanced Non-Small Cell Lung Cancer
    Starakis, Ioannis
    Nikolakopoulos, Achilleas
    Mazokopakis, Elias E.
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2012, 15 (08) : 641 - 655
  • [3] Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
    Kumar, Mukesh
    Ernani, Vinicius
    Owonikoko, Taofeek K.
    MOLECULAR ASPECTS OF MEDICINE, 2015, 45 : 55 - 66
  • [4] Targeted therapies in advanced non-small cell lung cancer: Success or failure?
    Szutowicz E.
    Konopa K.
    Jassem J.
    memo - Magazine of European Medical Oncology, 2011, 4 (1) : 23 - 26
  • [5] Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer
    Wang, Yuchang
    Chen, Rui
    Wa, Yue
    Ding, Shikuan
    Yang, Yijian
    Liao, Junbo
    Tong, Lei
    Xiao, Gelei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Targeted therapies for non-small cell lung cancer
    Papaetis, G. S.
    Roussos, C.
    Syrigos, K. N.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (27) : 2810 - 2831
  • [7] Targeted therapies for non-small cell lung cancer
    Dempke, Wolfram C. M.
    Suto, Tamas
    Reck, Martin
    LUNG CANCER, 2010, 67 (03) : 257 - 274
  • [8] Targeted therapies in non-small cell lung cancer
    Kyle, Fiona
    Spicer, James
    CANCER IMAGING, 2008, 8 (01): : 199 - 205
  • [9] Targeted therapies for non-small cell lung cancer
    Spicer, J
    Harper, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (09) : 1055 - 1062
  • [10] VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment
    Zhao, Yueshui
    Guo, Sipeng
    Deng, Jian
    Shen, Jing
    Du, Fukuan
    Wu, Xu
    Chen, Yu
    Li, Mingxing
    Chen, Meijuan
    Li, Xiaobing
    Li, Wanping
    Gu, Li
    Sun, Yuhong
    Wen, Qinglian
    Li, Jing
    Xiao, Zhangang
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (09): : 3845 - 3858